Flavin Adenine Dinucleotide (FAD) Pegylated (PEG)-Complexes: Proof of Concept (PoC) of theranostic tool on a Murine Breast Cancer Model.
Journal
Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
06
2021
accepted:
08
08
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
17
3
2022
Statut:
epublish
Résumé
Flavin adenine dinucleotide (FAD) plays a key role in an extensive range of cellular oxidation-reduction reactions, which is engaged in metabolic pathways. The purpose of this study was to realize pegylated flavins formulation, named FAD and FAD-PEG diacid complex as theranostic tool in cancer therapy. For this objective, a murine breast cancer model, which was induced by mouse-derived4T1 breast cancer cells was studied to assess the therapeutic efficacy of FAD (named NP1) and FAD-PEG diacid complex (named NP2). The cytokines were monitored to evaluate the serum inflammatory factors to develop the blood cell content of different groups of nude mice. The experimental model shows that an intravenous injection of FAD (NP1) can significantly reduce tumour volume, tumour index and thymus index, and decrease neutrophils (NE), monocytes (MO), eosinophils (EO), and basophils (BA). At the same time, the content of IL-1α, IL-12P70, TNF α, IL-1β and IL-6 was significantly reduced, and the content of IL-10 was significantly increased. These results provide the proof-of-concept for FAD as a smart adjuvant for cancer therapy and encourages their further development in the field of Nanomedicine.
Identifiants
pubmed: 34976592
doi: 10.7150/ntno.63496
pii: ntnov06p0175
pmc: PMC8671949
doi:
Substances chimiques
Flavin-Adenine Dinucleotide
146-14-5
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-183Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
ACS Appl Mater Interfaces. 2016 Aug 10;8(31):19946-57
pubmed: 27424920
Behav Brain Res. 2017 Jan 1;316:215-224
pubmed: 27599618
Int J Biol Macromol. 2019 Oct 1;138:986-995
pubmed: 31351152
Semin Cell Dev Biol. 2012 Jun;23(4):370-80
pubmed: 22306135
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Hematol Oncol Clin North Am. 2016 Apr;30(2):373-93
pubmed: 27040960
J Biol Chem. 2013 Oct 4;288(40):29069-80
pubmed: 23946482
Acta Crystallogr D Struct Biol. 2019 Sep 1;75(Pt 9):841-851
pubmed: 31478907
Nanotheranostics. 2021 Apr 22;5(4):405-416
pubmed: 33912380
Free Radic Biol Med. 2006 Apr 15;40(8):1293-302
pubmed: 16631519
Curr Drug Metab. 2007 Dec;8(8):822-9
pubmed: 18220563
Anal Chem. 2014 Oct 21;86(20):10223-30
pubmed: 25222439
J Org Chem. 2007 Aug 17;72(17):6329-42
pubmed: 17580897
Scientifica (Cairo). 2016;2016:9828672
pubmed: 27051561
Int J Nanomedicine. 2020 Mar 03;15:1437-1456
pubmed: 32184597
Commun Biol. 2019 Nov 14;2:414
pubmed: 31754644
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Biochem Biophys Res Commun. 2015 Sep 25;465(3):443-9
pubmed: 26277395
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
FEBS J. 2009 Jan;276(1):219-31
pubmed: 19049514
Front Immunol. 2019 Mar 06;10:360
pubmed: 30894857
Mediators Inflamm. 2013;2013:480739
pubmed: 23997430